Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split was approved by the Board of Directors and shareholders to maintain Nasdaq compliance.
This action will reduce the outstanding common stock from approximately 4.77 million shares to approximately 1.59 million shares.
Reverse Stock Split
Entero Therapeutics, Inc. is implementing a 1 for 3 reverse stock split to maintain Nasdaq compliance.
Board Approval
The reverse stock split was approved by the Board of Directors and shareholders of the company.
Share Reduction
The reverse stock split will reduce the outstanding common stock from 4.77 million shares to 1.59 million shares.
- The reverse stock split is a strategic move to enhance shareholder value and maintain Nasdaq listing compliance.
- Reducing the number of outstanding shares can lead to increased share price and market visibility for Entero Therapeutics, Inc.
The reverse stock split reflects Entero Therapeutics, Inc.'s commitment to maintaining market credibility and shareholder value.